{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:49:32Z","timestamp":1791434972644,"version":"4.3.3"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05975-6","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:50:49Z","timestamp":1791427849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agomelatine improves symptom severity and quality of life in diarrhea-predominant irritable bowel syndrome: insights from a randomized controlled clinical trial"],"prefix":"10.1007","author":[{"given":"Seyed Saman","family":"Talebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davoud","family":"Ahmadimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtabalsadat","family":"Mirjalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Keshavarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Zamanirafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Taghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Khazaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mehrpooya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"5","key":"5975_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17474124.2025.2493867","volume":"19","author":"AI Aliyu","year":"2025","unstructured":"Aliyu AI, Katsumata R, T\u00f6rnblom H, Simr\u00e9n M (2025) Gastrointestinal transit abnormalities in irritable bowel syndrome and their relation to symptoms. Expert Rev Gastroenterol Hepatol 19(5):447\u2013454","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"5975_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jaip.2024.01.021","volume":"12","author":"AA Alvarez","year":"2024","unstructured":"Alvarez AA, Palka JM, Khan DA (2024) Severe multiple drug intolerance syndrome in fibromyalgia and irritable bowel syndrome. J Allergy Clin Immunol Pract 12(5):1192\u20131201","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"5975_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40262-016-0386-3","volume":"55","author":"LPH Andersen","year":"2016","unstructured":"Andersen LPH, G\u00f6genur I, Rosenberg J, Reiter RJ (2016) Pharmacokinetics of melatonin: the missing link in clinical efficacy? Clin Pharmacokinet 55(9):1027\u20131030","journal-title":"Clin Pharmacokinet"},{"key":"5975_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-11-208","volume":"11","author":"DA Andrae","year":"2013","unstructured":"Andrae DA, Patrick DL, Drossman DA, Covington PS (2013) Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes 11:1\u201312","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"5975_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cgh.2006.09.003","volume":"4","author":"CN Bernstein","year":"2006","unstructured":"Bernstein CN (2006) The placebo effect for gastroenterology: tool or torment. Clin Gastroenterol Hepatol 4(11):1302\u20131308","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5975_CR6","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1023\/A:1020107915919","volume":"47","author":"GA Bubenik","year":"2002","unstructured":"Bubenik GA (2002) Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47:2336\u20132348","journal-title":"Dig Dis Sci"},{"issue":"17","key":"5975_CR7","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1056\/NEJMra1207068","volume":"367","author":"M Camilleri","year":"2012","unstructured":"Camilleri M (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367(17):1626\u20131635","journal-title":"N Engl J Med"},{"issue":"14","key":"5975_CR8","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1113\/jphysiol.2014.270892","volume":"592","author":"M Camilleri","year":"2014","unstructured":"Camilleri M (2014) Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol 592(14):2967\u20132980","journal-title":"J Physiol"},{"issue":"6","key":"5975_CR9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1053\/j.gastro.2008.09.005","volume":"135","author":"M Camilleri","year":"2008","unstructured":"Camilleri M, Chang L (2008) Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 135(6):1877\u20131891","journal-title":"Gastroenterology"},{"issue":"2","key":"5975_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/gast.2002.34780","volume":"123","author":"M Camilleri","year":"2002","unstructured":"Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, Mckinzie S, Urrutia R (2002) Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123(2):425\u2013432","journal-title":"Gastroenterology"},{"key":"5975_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/CLEP.S40245","volume":"6","author":"C Canavan","year":"2014","unstructured":"Canavan C, West J, Card T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6:71\u201380. https:\/\/doi.org\/10.2147\/CLEP.S40245","journal-title":"Clin Epidemiol"},{"key":"5975_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819878950","volume":"12","author":"DJ Cangemi","year":"2019","unstructured":"Cangemi DJ, Lacy BE (2019) Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Ther Adv Gastroenterol 12:1756284819878950","journal-title":"Ther Adv Gastroenterol"},{"issue":"2","key":"5975_CR13","first-page":"203","volume":"28","author":"M Carabotti","year":"2015","unstructured":"Carabotti M, Scirocco A, Maselli MA, Severi C (2015) The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Annals of Gastroenterol: Quarterly Publication of the Hellenic Society of Gastroenterology 28(2):203","journal-title":"Annals of Gastroenterol: Quarterly Publication of the Hellenic Society of Gastroenterology"},{"issue":"3","key":"5975_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jfma.2022.10.001","volume":"122","author":"K-H Chen","year":"2023","unstructured":"Chen K-H, Zeng B-Y, Zeng B-S, Sun C-K, Cheng Y-S, Su K-P, Wu Y-C, Chen T-Y, Lin P-Y, Liang C-S (2023) The efficacy of exogenous melatonin supplement in ameliorating irritable bowel syndrome severity: a meta-analysis of randomized controlled trials. J Formos Med Assoc 122(3):276\u2013285","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"5975_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1572-0241.2001.03804.x","volume":"96","author":"WY Chey","year":"2001","unstructured":"Chey WY, Jin HO, Lee MH, Sun SW, Lee KY (2001) Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 96(5):1499\u20131506","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"5975_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.2015.0954","volume":"313","author":"WD Chey","year":"2015","unstructured":"Chey WD, Kurlander J, Eswaran S (2015) Irritable bowel syndrome: a clinical review. JAMA 313(9):949\u2013958","journal-title":"JAMA"},{"key":"5975_CR17","volume":"10","author":"PP Chong","year":"2019","unstructured":"Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC (2019) The microbiome and irritable bowel syndrome\u2013a review on the pathophysiology, current research and future therapy. Front Microbiol 10:424646","journal-title":"Front Microbiol"},{"issue":"7","key":"5975_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/ajg.2011.86","volume":"106","author":"C Cremon","year":"2011","unstructured":"Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F (2011) Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106(7):1290\u20131298","journal-title":"Am J Gastroenterol"},{"key":"5975_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00007","volume":"4","author":"F De Ponti","year":"2013","unstructured":"De Ponti F (2013) Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol 4:7","journal-title":"Front Pharmacol"},{"issue":"6","key":"5975_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA, Hasler WL (2016) Rome IV\u2014functional GI disorders: disorders of gut-brain interaction. Gastroenterology 150(6):1257\u20131261","journal-title":"Gastroenterology"},{"issue":"6","key":"5975_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/MCG.0b013e318189a7f9","volume":"43","author":"DA Drossman","year":"2009","unstructured":"Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, Norton WF, Weinland SR, Dalton C, Leserman J, Bangdiwala SI (2009) International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 43(6):541\u2013550","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"5975_CR22","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/ajg.2011.201","volume":"106","author":"DA Drossman","year":"2011","unstructured":"Drossman DA, Chang L, Bellamy N, Gallo-Torres H, Lembo A, Mearin F, Norton N, Whorwell P (2011) Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 106(10):1749\u20131759","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"5975_CR23","doi-asserted-by":"publisher","first-page":"e26092","DOI":"10.7759\/cureus.26092","volume":"29","author":"H Elsaygh","year":"2022","unstructured":"Elsaygh H, Alhafez I, Jaber M, Al-Rasheed M, Zaher A, ElSaygh J (2022) A literature review of major clinical trials that contributed to treatment protocols of irritable bowel syndrome with diarrhea. Cureus 29(11):e26092. https:\/\/doi.org\/10.7759\/cureus.26092","journal-title":"Cureus"},{"issue":"2","key":"5975_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11(2):395\u2013402","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5975_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00001574-200003000-00004","volume":"16","author":"MD Gershon","year":"2000","unstructured":"Gershon MD (2000) 5-HT (serotonin) physiology and related drugs. Curr Opin Gastroenterol 16(2):113\u2013120","journal-title":"Curr Opin Gastroenterol"},{"key":"5975_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2036.2004.02180.x","volume":"20","author":"MD Gershon","year":"2004","unstructured":"Gershon MD (2004) Serotonin receptors and transporters\u2014roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20:3\u201314","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"5975_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.14309\/ajg.0000000000001247","volume":"116","author":"VC Goodoory","year":"2021","unstructured":"Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC (2021) Impact of psychological comorbidity on the prognosis of irritable bowel syndrome. Am J Gastroenterol 116(7):1485\u20131494","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"5975_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1053\/gast.2000.16484","volume":"119","author":"IM Gralnek","year":"2000","unstructured":"Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA (2000) The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119(3):654\u2013660","journal-title":"Gastroenterology"},{"issue":"59","key":"5975_CR29","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.18632\/oncotarget.19682","volume":"8","author":"T Guan","year":"2017","unstructured":"Guan T, Li T, Cai W, Huang D, Ouyang P, Wang Y, Chen H, Wu K, Ma X (2017) HTR3A and HTR3E gene polymorphisms and diarrhea predominant irritable bowel syndrome risk: evidence from a meta-analysis. Oncotarget 8(59):100459","journal-title":"Oncotarget"},{"issue":"15","key":"5975_CR30","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan M, Munoz C, Moca\u00ebr E (2014) Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 171(15):3604\u20133619","journal-title":"Br J Pharmacol"},{"issue":"45","key":"5975_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035871","volume":"102","author":"Y-H Guo","year":"2023","unstructured":"Guo Y-H, Zhou L, Cui Z-A, Wang J, Zhang L, Xu T, Xie Y-D, Chen H (2023) Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: a meta-analysis. Medicine (Baltimore) 102(45):e35871","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"5975_CR32","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.5455\/annalsmedres.2022.05.156","volume":"29","author":"E Kacar","year":"2022","unstructured":"Kacar E, Sahinturk S, Yardimci A, Ulker N, Tan F, Bulmus O, Ercan Z, Serhatlioglu I (2022) Effect of agomelatine on intestinal smooth muscle contractility in rats. Ann Med Res 29(11):1258\u20131262","journal-title":"Ann Med Res"},{"key":"5975_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13030-021-00205-2","volume":"15","author":"A Khalilian","year":"2021","unstructured":"Khalilian A, Ahmadimoghaddam D, Saki S, Mohammadi Y, Mehrpooya M (2021) A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. BioPsychoSoc Med 15:1\u201312","journal-title":"BioPsychoSoc Med"},{"issue":"10","key":"5975_CR34","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/j.1572-0241.2000.03177.x","volume":"95","author":"D-Y Kim","year":"2000","unstructured":"Kim D-Y, Camilleri M (2000) Serotonin: a mediator of the brain\u2013gut connection. Am J Gastroenterol 95(10):2698\u20132709","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"5975_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5455\/bcp.20130925022745","volume":"24","author":"Y Kivrak","year":"2014","unstructured":"Kivrak Y, Karademir B, Aygun H, Ersan Y, Ari M, Karaahmet E, Yagci I (2014) The effect of agomelatine on the nociceptive system. Klin Psikofarmakol Bul 24(3):220\u2013225","journal-title":"Klin Psikofarmakol Bul"},{"issue":"3","key":"5975_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1192\/bjp.bp.112.120196","volume":"203","author":"M Koesters","year":"2013","unstructured":"Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C (2013) Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 203(3):179\u2013187","journal-title":"Br J Psychiatry"},{"issue":"2","key":"5975_CR37","first-page":"139","volume":"62","author":"P Konturek","year":"2011","unstructured":"Konturek P, Brzozowski T, Konturek S (2011) Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 62(2):139\u2013150","journal-title":"J Physiol Pharmacol"},{"issue":"6","key":"5975_CR38","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.pharep.2017.05.014","volume":"69","author":"A Ku\u0142ak-Bejda","year":"2017","unstructured":"Ku\u0142ak-Bejda A, Bejda G, Waszkiewicz N (2017) Antidepressants for irritable bowel syndrome\u2014a systematic review. Pharmacol Rep 69(6):1366\u20131379","journal-title":"Pharmacol Rep"},{"issue":"11","key":"5975_CR39","first-page":"729","volume":"7","author":"BE Lacy","year":"2011","unstructured":"Lacy BE, Gabbard SL, Crowell MD (2011) Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air? Gastroenterol Hepatol (n Y) 7(11):729","journal-title":"Gastroenterol Hepatol (n Y)"},{"key":"5975_CR40","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S216056","author":"R Liu","year":"2020","unstructured":"Liu R, Staller K (2020) Update on eluxadoline for the treatment of irritable bowel syndrome with diarrhea: patient selection and perspectives. Drug des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S216056","journal-title":"Drug des Devel Ther"},{"issue":"5","key":"5975_CR41","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"GF Longstreth","year":"2006","unstructured":"Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130(5):1480\u20131491","journal-title":"Gastroenterology"},{"key":"5975_CR42","doi-asserted-by":"publisher","first-page":"174480692311700","DOI":"10.1177\/17448069231170072","volume":"19","author":"M-D Lv","year":"2023","unstructured":"Lv M-D, Wei Y-X, Chen J-P, Cao M-Y, Wang Q-L, Hu S (2023) Melatonin attenuated chronic visceral pain by reducing Nav1.8 expression and nociceptive neuronal sensitization. Mol Pain 19:17448069231170072","journal-title":"Mol Pain"},{"issue":"1","key":"5975_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40360-022-00612-3","volume":"23","author":"SM Mahdavi","year":"2022","unstructured":"Mahdavi SM, Shariati B, Shalbafan M, Rashedi V, Yarahmadi M, Ghaznavi A, Amiri S (2022) The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial. BMC Pharmacol Toxicol 23(1):70","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"5975_CR44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.phrs.2009.11.014","volume":"62","author":"M Maldonado","year":"2010","unstructured":"Maldonado M, Mora-Santos M, Naji L, Carrascosa-Salmoral M, Naranjo M, Calvo J (2010) Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 62(3):282\u2013287","journal-title":"Pharmacol Res"},{"issue":"2","key":"5975_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0976-500X.72369","volume":"1","author":"S Manikandan","year":"2010","unstructured":"Manikandan S (2010) Agomelatine: a novel melatonergic antidepressant. J Pharmacol Pharmacother 1(2):122","journal-title":"J Pharmacol Pharmacother"},{"issue":"6","key":"5975_CR46","first-page":"492","volume":"18","author":"N Masaeli","year":"2013","unstructured":"Masaeli N, Kheirabadi GR, Afshar H, Daghaghzadeh H, Maracy MR, Assadolahi F, Adibi P (2013) Validity, reliability, and factor analysis of Persian version of quality of life questionnaire for irritable bowel syndrome (IBS-QOL-34). J Res Med Sci 18(6):492","journal-title":"J Res Med Sci"},{"issue":"3","key":"5975_CR47","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1172\/JCI76304","volume":"125","author":"EA Mayer","year":"2015","unstructured":"Mayer EA, Tillisch K, Gupta A (2015) Gut\/brain axis and the microbiota. J Clin Invest 125(3):926\u2013938","journal-title":"J Clin Invest"},{"key":"5975_CR48","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1097\/MCG.0b013e31821fbf44","volume":"45","author":"H M\u00f6nnikes","year":"2011","unstructured":"M\u00f6nnikes H (2011) Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol 45:S98\u2013S101","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"5975_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-14","volume":"1","author":"A Montazeri","year":"2003","unstructured":"Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S (2003) The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes 1(1):14","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"5975_CR50","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/apt.13378","volume":"42","author":"Z Mujagic","year":"2015","unstructured":"Mujagic Z, Keszthelyi D, Aziz Q, Reinisch W, Quetglas E, De Leonardis F, Segerdahl M, Masclee A (2015) Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment Pharmacol Ther 42(9):1064\u20131081","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5975_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, Janecek E, Domecq C, Greenblatt D (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"5975_CR52","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/jcpt.12749","volume":"43","author":"QX Ng","year":"2018","unstructured":"Ng QX, Soh AYS, Lim DY, Yeo WS (2018) Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome. J Clin Pharm Ther 43(5):752\u2013756","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"5975_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.dld.2006.10.014","volume":"39","author":"L \u00d6hman","year":"2007","unstructured":"\u00d6hman L, Simren M (2007) New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 39(3):201\u2013215","journal-title":"Dig Liver Dis"},{"issue":"22","key":"5975_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226948","volume":"13","author":"AJ Papale","year":"2024","unstructured":"Papale AJ, Flattau R, Vithlani N, Mahajan D, Nadella S (2024) A review of pharmacologic and non-pharmacologic therapies in the management of irritable bowel syndrome: current recommendations and evidence. J Clin Med 13(22):6948","journal-title":"J Clin Med"},{"issue":"2","key":"5975_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1023\/A:1018831127942","volume":"43","author":"DL Patrick","year":"1998","unstructured":"Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL (1998) Quality of life in persons with irritable bowel syndrome (development and validation of a new measure). Dig Dis Sci 43(2):400\u2013411","journal-title":"Dig Dis Sci"},{"key":"5975_CR56","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S42789","author":"BK Plesni\u010dar","year":"2014","unstructured":"Plesni\u010dar BK (2014) Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence. https:\/\/doi.org\/10.2147\/PPA.S42789","journal-title":"Patient Prefer Adherence"},{"key":"5975_CR57","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1097\/01.yic.0000195659.99148.09","volume":"21","author":"F Rouillon","year":"2006","unstructured":"Rouillon F (2006) Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 21:S31\u2013S35","journal-title":"Int Clin Psychopharmacol"},{"issue":"22","key":"5975_CR58","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.3748\/wjg.v20.i22.6759","volume":"20","author":"L Saha","year":"2014","unstructured":"Saha L (2014) Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol WJG 20(22):6759","journal-title":"World J Gastroenterol WJG"},{"issue":"6","key":"5975_CR59","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.eurpsy.2008.04.002","volume":"23","author":"L San","year":"2008","unstructured":"San L, Arranz B (2008) Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 23(6):396\u2013402","journal-title":"Eur Psychiatry"},{"issue":"4","key":"5975_CR60","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5056\/jnm.2013.19.4.433","volume":"19","author":"AY Seo","year":"2013","unstructured":"Seo AY, Kim N, Oh DH (2013) Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil 19(4):433","journal-title":"J Neurogastroenterol Motil"},{"issue":"10","key":"5975_CR61","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.3748\/wjg.v20.i10.2492","volume":"20","author":"KTH Siah","year":"2014","unstructured":"Siah KTH, Wong RKM, Ho KY (2014) Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol: WJG 20(10):2492","journal-title":"World J Gastroenterol: WJG"},{"issue":"1\u20132","key":"5975_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cca.2009.01.028","volume":"403","author":"A Sikander","year":"2009","unstructured":"Sikander A, Rana SV, Prasad KK (2009) Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 403(1\u20132):47\u201355","journal-title":"Clin Chim Acta"},{"issue":"26","key":"5975_CR63","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.3748\/wjg.v21.i26.8103","volume":"21","author":"P Singh","year":"2015","unstructured":"Singh P, Staller K, Barshop K, Dai E, Newman J, Yoon S, Castel S, Kuo B (2015) Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol WJG 21(26):8103","journal-title":"World J Gastroenterol WJG"},{"issue":"3","key":"5975_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120195","volume":"10","author":"F S\u00f6derquist","year":"2015","unstructured":"S\u00f6derquist F, Hellstr\u00f6m PM, Cunningham JL (2015) Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2. PLoS ONE 10(3):e0120195","journal-title":"PLoS ONE"},{"issue":"9","key":"5975_CR65","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41575-023-00794-z","volume":"20","author":"HM Staudacher","year":"2023","unstructured":"Staudacher HM, Black CJ, Teasdale SB, Mikocka-Walus A, Keefer L (2023) Irritable bowel syndrome and mental health comorbidity\u2014approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol 20(9):582\u2013596","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"5975_CR66","first-page":"284","volume":"38","author":"MJ Temido","year":"2025","unstructured":"Temido MJ, Cristiano M, Gouveia C, Mesquita B, Figueiredo P, Portela F (2025) Antidepressants in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol 38(3):284","journal-title":"Ann Gastroenterol"},{"issue":"8","key":"5975_CR67","doi-asserted-by":"publisher","first-page":"1341-a","DOI":"10.1176\/appi.ajp.157.8.1341-a","volume":"157","author":"SG Thomas","year":"2000","unstructured":"Thomas SG (2000) Irritable bowel syndrome and mirtazapine. Am J Psychiatry 157(8):1341-a-1342","journal-title":"Am J Psychiatry"},{"issue":"3","key":"5975_CR68","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1192\/bjp.bp.108.061960","volume":"195","author":"R Uher","year":"2009","unstructured":"Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A (2009) Adverse reactions to antidepressants. Br J Psychiatry 195(3):202\u2013210","journal-title":"Br J Psychiatry"},{"issue":"6","key":"5975_CR69","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.gpb.2020.06.013","volume":"18","author":"B Wang","year":"2020","unstructured":"Wang B, Zhu S, Liu Z, Wei H, Zhang L, He M, Pei F, Zhang J, Sun Q, Duan L (2020) Increased expression of colonic mucosal melatonin in patients with irritable bowel syndrome correlated with gut dysbiosis. Genomics Proteomics Bioinformatics 18(6):708\u2013720","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"2","key":"5975_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JCP.0b013e3181d420a7","volume":"30","author":"J Zajecka","year":"2010","unstructured":"Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A (2010) Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30(2):135\u2013144","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"5975_CR71","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2013370","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"5975_CR72","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1021\/jm401343c","volume":"57","author":"DP Zlotos","year":"2014","unstructured":"Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA (2014) MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 57(8):3161\u20133185","journal-title":"J Med Chem"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05975-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:02:11Z","timestamp":1791432131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":72,"alternative-id":["5975"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05975-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent prior to study participation, and the study protocol was approved by the ethics committee at Hamadan University of Medical Sciences (IR.UMSHA.REC.1403.620).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No consent for publication was required as no identifiable data are included.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}